Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improving Immune Response to Hepatitis B Vaccine in HIV-positive Subjects Using GM-CSF
NCT00272493Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sargramostim in hepatitis B (HBV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Quantitative hepatitis B surface antibody at 16 weeks and Occurrence of Grade 3 or higher adverse events and HIV viral load increase greater than 1 log10 at 60 weeks. Status: completed.
02
Drugs
sargramostim
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00272493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272493.